• SARS-CoV-2 N Protein Inhibits GADD34-Mediated Innate Immunit

  2026-07-17

  Liu et al. reveal a novel mechanism by which the SARS-CoV-2 nucleocapsid protein impairs host antiviral defense: by sequestering GADD34 mRNA in atypical foci, it disrupts IRF3-mediated interferon responses. These insights refine our understanding of coronavirus immune evasion and highlight potential targets for therapeutic intervention.

• Ferulic Acid Targets ER Stress to Alleviate Chemotherapy-Ind

  2026-07-17

  This study reveals that ferulic acid (FA) mitigates chemotherapy-induced premature ovarian insufficiency (POI) by targeting ER stress pathways in granulosa cells and ovarian tissue. The findings clarify the molecular basis of FA’s protective effects and suggest new directions for POI therapeutics.

• Cinoxacin in Research: Quinolone Antibiotic Workflows & Opti

  2026-07-16

  Cinoxacin, a potent quinolone antibiotic, offers researchers precision in studying Gram-negative uropathogens and antibiotic resistance mechanisms. This article delivers granular workflow enhancements, troubleshooting, and data-driven insights for maximizing experimental reproducibility and translational impact.

• Minoxidil Sulphate in Vascular Biology: Applied Protocols &

  2026-07-16

  Leverage Minoxidil sulphate as a potent tool for dissecting vasodilation pathways and potassium channel dynamics in renal and vascular research. This guide translates recent breakthroughs into actionable protocols, with troubleshooting and optimization strategies for reproducible results in sepsis and hair growth biology.

• EZ Cap™ Cas9 mRNA (m1Ψ): Enhancing Genome Editing Precision

  2026-07-15

  EZ Cap™ Cas9 mRNA (m1Ψ) empowers researchers to achieve high-fidelity CRISPR-Cas9 genome editing with minimized immune activation and robust translation in mammalian cells. This advanced mRNA with Cap1 structure, supplied by APExBIO, offers workflow flexibility and superior editing outcomes compared to conventional Cas9 delivery methods.

• Optimizing Glycogen Analysis with the Glycogen Colorimetric

  2026-07-15

  The Glycogen Colorimetric Assay Kit II streamlines sensitive, high-throughput glycogen quantification, even in complex biological matrices. Its robust design ensures reliable performance for metabolic and circadian research, as demonstrated by recent breakthroughs in exercise timing studies.

• ECL Chemiluminescent Substrate Detection Kit: Ultra-Sensitiv

  2026-07-14

  Achieve reliable detection of low-abundance proteins using the ECL Chemiluminescent Substrate Detection Kit (Hypersensitive), featuring extended signal duration and minimized background. This guide unpacks workflow optimization, real-world troubleshooting, and protocol enhancements to empower researchers working at the forefront of protein analysis.

• AR Heterogeneity Drives Divergent Prostate Cancer Therapy Re

  2026-07-14

  This study reveals that androgen receptor (AR) expression heterogeneity in prostate cancer underlies distinct biological behaviors and treatment outcomes. By dissecting AR-positive and AR-low cell populations, the research provides mechanistic insights that may inform precision therapy development for castration-resistant prostate cancers.

• NEDD4L Suppresses Colorectal Cancer Liver Metastasis via PRM

  2026-07-13

  This study identifies NEDD4L as a key E3 ligase that limits colorectal cancer liver metastasis by driving the ubiquitin-mediated degradation of PRMT5, thereby attenuating AKT/mTOR pathway activity. These findings advance the mechanistic understanding of metastasis suppression and suggest new avenues for targeting cancer progression.

• 2-D08 (2’,3’,4’-trihydroxyflavone): Selective SUMOylation In

  2026-07-13

  2-D08 (2’,3’,4’-trihydroxyflavone) is a potent, mechanistically unique inhibitor of protein sumoylation. It specifically blocks SUMO transfer from UBC9-SUMO thioester to substrates, without affecting E1 or Ubc9-SUMO thioester formation. This selectivity enables precise modulation of posttranslational modification networks in cancer and mitochondrial research applications.

• Bicontinuous Nanostructures in CART-Mediated mRNA Delivery

  2026-07-12

  The referenced study characterizes the self-assembly and internal architecture of RNA-loaded nanoparticles formed with amphiphilic Charge-Altering Releasable Transporters (CARTs). By integrating advanced structural analyses, the work reveals how polymer chemistry and cargo type dictate bicontinuous morphologies, informing the design of efficient polymer-based mRNA delivery vectors.

• Zosuquidar (LY335979): Disrupting Multidrug Resistance in Ca

  2026-07-10

  Zosuquidar (LY335979) 3HCl is a benchmark P-glycoprotein inhibitor enabling precise reversal of multidrug resistance in cancer research. This guide details robust experimental workflows, troubleshooting strategies, and insights from cutting-edge resistance studies to maximize the translational utility of Zosuquidar in oncology assays.

• Acridine Orange hydrochloride for Differential DNA/RNA Stain

  2026-07-09

  Acridine Orange hydrochloride offers robust, membrane-permeable nucleic acid staining for workflows that require differential detection of DNA and RNA. It is suitable for cell cycle analysis, apoptosis detection, and flow cytofluorometric applications, but should not be used in protocols that demand long-term storage of dye solutions or highly sequence-specific nucleic acid discrimination.

• Disrupting SARS-CoV-2 Nucleocapsid Phase Separation: Mechani

  2026-07-09

  The reference study uncovers that SARS-CoV-2 nucleocapsid (N) protein undergoes RNA-driven liquid–liquid phase separation (LLPS), a process critical for viral replication. By demonstrating that (-)-gallocatechin gallate (GCG) disrupts N protein LLPS and inhibits viral replication, the work provides mechanistic detail for targeting condensate formation as a potential antiviral strategy.

• TRIM21 Drives ERK1/2 Activation and Drug Resistance in PAs

  2026-07-08

  This study demonstrates that TRIM21 mediates ERK1/2 ubiquitination and phosphorylation, promoting cell proliferation and drug resistance in pituitary adenomas. The research also identifies Quisinostat (JNJ-26481585) as an HDAC inhibitor capable of downregulating TRIM21, providing a new strategy to overcome therapeutic resistance.

451 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page